Shattuck Labs’ stock saw a 74% increase in December after an analyst upgraded the recommendation to buy and set a price target of $6 per share. The boost was due to SL-325, an investigational drug targeting inflammatory and immune-mediated disorders. The FDA cleared its IND application, and a Phase 1 trial began with funds raised from a private round. The company also showed improved financial discipline, narrowing net losses and reducing expenses. With potential for multiple indications, Shattuck Labs looks promising for investors seeking growth opportunities in the biotech sector.

Read more at Nasdaq: Why Shattuck Labs Stock Soared in December